Loading…
Employees: 73
Size Aclaris Therapeutics (ACRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $604M, the 2579th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.90 on 6 Nov 2026.
Performance Over six months the shares fell 20.9%, against -21.4% for the median peer and -1.1% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 51.0% over the last twelve months (peer median -1.7%); the operating margin is -1,040.4% (peer median 4.7%).
Valuation It trades at 62.6× enterprise value to sales against a peer median of 3.3× (3rd most expensive of 18).
Capital Return on invested capital runs 203.4 points below its cost of capital (9.7% WACC).
Short interest Short interest is 10.2% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $8.22M | $7.83M | $18.7M | $31.2M | $29.8M |
| Revenue growth | — | -58% | -40% | +5% | — |
| Gross profit | $1.06M | $542,000 | $3.46M | $13.2M | $17.8M |
| EBITDA | -$85.0M | -$73.4M | -$49.0M | -$114M | -$84.4M |
| Net income | -$75.7M | -$64.9M | -$132M | -$88.5M | -$86.9M |
| Free cash flow | -$62.2M | -$47.2M | -$20.2M | -$79.6M | -$68.2M |
| Capital expenditure | -$715,000 | $111,000 | $35.9M | $1.31M | $605,000 |
| Total debt | $1.85M | $2.12M | $2.60M | $3.50M | $2.25M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ACRS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.9% | -6.4% | 5th highest of 21 |
| 6-month return | -20.9% | -21.4% | 10th highest of 21 |
| Distance from 52-week high | -40.9% | -35.8% | 8th lowest of 21 |
| Revenue growth (TTM) | -51.0% | -1.7% | 3rd lowest of 18 |
| Operating margin | -1,040.4% | 4.7% | 2nd lowest of 18 |
| EV / Sales | 62.6× | 3.3× | 3rd most expensive of 18 |
| ROIC minus cost of capital | -203.4 pp | -0.8 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 2.2× | -14.3% | +2.8% |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 3.3× | 25.4% | +31.4% |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 2.0× | 14.8% | +9.7% |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | 0.8× | 5.0% | +5.0% |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | 7.1× | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 1.0× | -4.9% | +6.5% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | 107.7× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | 2.5× | 12.1% | -5.9% |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |